Please login to the form below

Not currently logged in
Email:
Password:

telaprevir

This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.

Leiden reassures on key role at Vertex

Leiden reassures on key role at Vertex

The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.

Latest news

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...